Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review

por Janoudi, Ghayath, Amegatse, William, McIntosh, Brendan, Sehgal, Chander, Richter, Trevor
Publicado 2016

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications

por Salek, Sam M., Lussier Hoskyn, Sarah, Johns, Jeffrey, Allen, Nicola, Sehgal, Chander
Publicado 2019

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans

por Salek, Sam, Lussier Hoskyn, Sarah, Johns, Jeffrey Roy, Allen, Nicola, Sehgal, Chander
Publicado 2019

Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer

por Hannouf, Malek B., Sehgal, Chander, Cao, Jeffrey Q., Mocanu, Joseph D., Winquist, Eric, Zaric, Gregory S.
Publicado 2012